A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

Abstract	Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking D-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.
Authors	E Goodall, C Oxtoby, R Richards, G Watkinson, D Brown, T Silverstone
Journal	The British journal of psychiatry : the journal of mental science (Br J Psychiatry) Vol. 153 Pg. 208-13 (Aug 1988) ISSN: 0007-1250 [Print] England
PMID	2908235 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antipsychotic Agents Fenfluramine
Topics	Adult Antipsychotic Agents (adverse effects) Clinical Trials as Topic Double-Blind Method Female Fenfluramine (adverse effects, blood, therapeutic use) Humans Male Middle Aged Obesity (blood, chemically induced, drug therapy) Schizophrenia (complications, drug therapy) Weight Loss (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!